Butterfly Medical has also submitted a premarket approval application to the FDA.
|Articles|June 1, 2003
Attract the media with an effective news release
A catchy headline or photo will grab attention and result in positivepublic relationsHealth and wellness topics are hot, and the media is interested in newmedical technologies, surgical procedures, and diagnostic techniques, aswell as fascinating medical cases with human-interest angles. Never beforehave medical practices had more opportunities for positive media exposure.
Advertisement
Advertisement
Related to this article
Moderators and participants reviewed ARANOTE, ARACOG, and ARASEC data and how they inform individualized treatment for mCSPC.
Timothy N. Clinton, MD, recaps bladder cancer data from the 2026 AUA Northeastern Section meeting, including BOND-003 cretostimogene results and safety data on mitomycin intravesical solution.
Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
Sandip Prasad, MD, MPhil, discusses ENVISION trial findings on mitomycin for intravesical solution and patient selection in clinical practice.
OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.
Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.
Advertisement
Advertisement
Trending on Urology Times
1
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
2
Butterfly Prostatic Retraction Device granted EU MDR certification for BPH
3
Matching mCSPC treatment to the patient, not just the trial data
4
Timothy Clinton, MD, reviews bladder cancer data from 2026 AUA Northeastern Section Meeting
5